



Intercell completes acquisition of Pelias

- » 100 % of Pelias shares acquired in an all-share deal; former shareholders of Pelias receive 349,815 new Intercell shares from capital increase
- » Intercell's product portfolio strengthened by clinical stage Pseudomonas vaccine candidate - focus on expanding Intercell's leading position as technology provider and vaccine developer in the field of hospital-acquired infections

Vienna (Austria), January 15, 2007 – Intercell AG (VSE; „ICLL“) announced today that the acquisition of Pelias Biomedical Development AG, Vienna (Austria) was completed with a capital increase. 349.815 new shares, which represent about 0.9 percent of Intercell's current share capital, were issued to the former Pelias shareholders in return for transferring their Pelias shares to Intercell. The transaction had been announced in an ad-hoc statement on December 6, 2006.

The 349,815 new shares start trading at the Vienna Stock Exchange on January 17, 2006. After completion of the capital increase, Intercell's total number of shares issued amounts to 39,881,712.

Pelias will remain a separate legal entity operating as a subsidiary of Intercell AG. Pelias develops products and holds certain licenses in the field of vaccines against important pathogens involved in hospital-acquired infections, including a clinical stage Pseudomonas vaccine candidate and a number of antigens, which have been identified by Intercell's proprietary Antigen Identification Program (AIP®). Hospital-acquired infections are one of the major causes of death and serious illness worldwide and result in an annual burden of USD 20 billion in the developed world.

About hospital-acquired infections

Nosocomial infections – or hospital acquired infections - are bacterial or fungal infections which are acquired in a hospital setting and cause a variety of severe infections, many life-threatening such as pneumonia, sepsis and bacteremia. Each year, around 2 million infections and 100,000 deaths occur in the US alone due to nosocomial infections. The annual burden to the society is constantly increasing due to the antibiotics resistance of the most problematic bacteria. In the field of S. aureus infections Intercell has a strong strategic alliance with Merck & Co., Inc. with a vaccine product in clinical trials.

About Intercell AG:

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical





need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and S. aureus, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303 Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.